[1]叶海琼,傅晓冬*.microRNA-19a在妊娠期高血压疾病孕妇外周血中的表达[J].中国计划生育和妇产科,2016,(6):17-20.
　YE Hai-qiong,Fu Xiao-dong*.Different expression of microRNA-19a in the peripheral blood in pregnant women with hypertensive disorder[J].Chinese Journal of Family Planning & Gynecotokology,2016,(6):17-20.
点击复制

microRNA-19a在妊娠期高血压疾病孕妇外周血中的表达
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2016年6期
页码:
17-20
栏目:
论著与临床
出版日期:
2016-06-25

文章信息/Info

Title:
Different expression of microRNA-19a in the peripheral blood in pregnant women with hypertensive disorder
作者:
叶海琼; 傅晓冬*
泸州医学院附属医院妇产科
Author(s):
YE Hai-qiong; Fu Xiao-dong*
Department of gynaecology and obstetrics,The Affiliated Hospital of Luzhou Medical College, Luzhou Sichuan 646000，P.R.China
关键词:
妊娠期高血压疾病; 血浆; miR-19a; 差异性表达
Keywords:
hypertensive disorder complicating pregnancy;  peripheral blood;  miR-19a ;  differential expression
分类号:
R 714.24
摘要:
目的分析妊娠期高血压疾病孕妇与正常孕妇血浆中microRNA-19a（miR-19a）的差异性表达特征，并探讨其临床应用。方法选择2013年1月至2015年6月泸州医学院附属医院收治的妊娠期高血压疾病孕妇90例作为妊娠期高血压疾病组，按孕妇病情再分为妊娠期高血压组（30例）、轻度子痫前期组（30例）、重度子痫前期组（30例）。另选择同期在本院行孕检的30例健康孕妇作为正常组，应用实时荧光定量聚合酶链式反应测定不同组孕妇血浆中miR-19a的相对表达量，比较妊娠期高血压疾病组与正常组孕妇miR-19a的表达差异，并分类统计比较妊娠期高血压疾病各亚组miR-19a表达量，评估miR-19a的临床诊断应用价值。结果与正常组比较，妊娠期高血压疾病组miR-19a表达量显著升高（P＜005）；不同妊娠期高血压疾病亚组miR-19a表达量比较，重度子痫前期组miR-19a表达量最高，其后依次为轻度子痫前期组、妊娠期高血压组、正常组（P＜005）。结论妊娠期高血压疾病孕妇与正常孕妇血浆中miR-19a表达量存在差异性，妊娠期高血压疾病孕妇血浆中存在升高趋势，对于妊娠期高血压疾病的临床诊断具有一定指导意义。
Abstract:
ObjectiveTo analyze the difference of microRNA-19a（miR-19a） in the peripheral blood in normal pregnant women and pregnant women with hypertensive disorder, and to explore its clinical application. Methods90 pregnant women with hypertensive disorder hospitalized in The Affiliated Hospital of Luzhou Medical College from January 2013 to June 2015 were selected as hypertensive disorder complicating pregnancy (HDCP) group, according to the condition of illness, they were divided into gestational hypertension group (30 cases), mild preeclampsia group (30 cases) and severe preeclampsia group (30 cases). 30 healthy pregnant women during the same time were selected as normal group, the expression of miR-19a in different groups was measured, and the expression of miR-19a was compared with that of normal group, and the clinical value of miR-19a expression was evaluated. ResultsCompared with normal group, the expression of miR-19a was significantly increased in patients with HDCP group (P＜005), and the difference between the groups was statistically significant. The expression of miR-19a in severe preeclampsia group was the highest, which was significantly higher than that in the normal group, the gestational hypertension group and mild preeclampsia group (P＜005). ConclusionThe expression of miR-19a in pregnant women with HDCP is different from that in normal pregnant women, and there is an increasing trend in the peripheral blood in pregnant women with HDCP, which has certain guiding significance for clinical diagnosis and prognosis of HDCP.

参考文献/References:

［1］段练，熊兴江，王阶．MicroRNA与高血压病 ［J］．中国中药杂志， 2014， 39 （3）： 397-401． ［2］刘辉，王伟明，左群．妊娠期高血压发病影响因素病例对照研究 ［J］．中国公共卫生， 2012， 28 （3）： 270-272． ［3］QIN Xiaomei, WANG Xiaohong, WANG Ying, et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells ［J］. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107 (7): 3240-3244. ［4］HUANG Yong, SHEN Xing-jia, ZOU Quan, et al. Biological functions of MicroRNAs ［J］. Russian Journal of Bioorganic Chemistry, 2010, 36 (6): 684-689. ［5］SCHIRLE N T. Gene regulation:Structural basis for microRNA targeting ［J］. Science. 2014, 346 (6209): 608-613. ［6］马东青，崔红．miRNA体内转染的研究进展 ［J］．临床和实验医学杂志， 2014,13 （21）： 1825-1829． ［7］于曼，张建华，张华．妊娠期高血压疾病的临床流行病学分析 ［J］．实用妇产科杂志， 2012， 28 （7）： 581-585． ［8］李文婷，田甜，冯胜娟，等．浅析microRNA在疾病中作用的认识历程 ［J］．医学与哲学， 2014， 5 （18）： 59-62． ［9］李晓菲，吴青青，王琪，等．妊娠中晚期子宫-胎盘-胎儿循环与妊娠期高血压疾病进展程度的相关研究 ［J］．中国妇产科临床杂志， 2013， 14 （2）： 123-127． ［10］崔明花，金光．miRNA靶标及Poly-miRTS预测软件的研究进展 ［J］．延边大学医学学报， 2014, 37 （3）： 224-227． ［11］费明钰. microRNA-210在妊娠期高血压疾病中的诊断应用及调控机制研究 ［D］.上海:第二军医大学, 2010： 15. ［12］王艺璇，刘媛圆，李明瑛，等．microRNA作为高血压病治疗靶点的初步实验研究 ［J］．山东医药， 2012， 52 （4）： 11-13, 16．

相似文献/References:

[1]黄辉秀,谭毅.妊娠期高血压疾病预测和预防的研究现状[J].中国计划生育和妇产科,2009,(05):0.
　HUANG Hui-xiu,TAN Yi MCH Hospital of Fangcheng urban district,Fangchenggang city Guangxi automous region 80,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(6):0.
[2]张珺,仲红丽.妊娠期高血压疾病监测系统预测及早期干预520例临床分析[J].中国计划生育和妇产科,2009,(06):0.
[3]肖兵,高岩,熊庆,等.妊娠期高血压疾病的流行病学研究进展[J].中国计划生育和妇产科,2010,(01):0.
[4]何怡,赵可文,唐莉,等.卡孕栓防治妊娠期高血压疾病产后出血的疗效观察[J].中国计划生育和妇产科,2010,(02):0.
　HE Yi,ZHAO Ke-wen,TANG LiMCH hospital of Dongguan city,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[5]庞春蓉,傅晓冬.肾上腺髓质素与妊娠期高血压疾病[J].中国计划生育和妇产科,2010,(02):0.
[6]陈倩,段成城,傅晓冬,等.血清T辅助细胞比率与妊娠期高血压疾病的关系和意义[J].中国计划生育和妇产科,2010,(03):0.
　CHEN Qian,DUAN Cheng-cheng,FU Xiao-dong..[J].Chinese Journal of Family Planning & Gynecotokology,2010,(6):0.
[7]陈茜松,刘丽俊,季淑英,等.妊娠期高血压疾病患者血清抵抗素水平的变化及其临床意义[J].中国计划生育和妇产科,2011,(03):0.
　CHEN Qian-song,LIU Li-jun,JI Shu-ying.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(6):0.
[8]侯卫萍,程兰,黄立,等.血清胱抑素C在妊娠期高血压疾病中的应用[J].中国计划生育和妇产科,2011,(06):0.
　HOU Wei-ping,CHENG Lan,HUANG Li.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(6):0.
[9]刘圣英,杨建恩.孕期补钙预防高危孕妇妊娠期高血压疾病的临床观察[J].中国计划生育和妇产科,2012,(03):0.
　LIU Sheng-ying,YANG Jian-en.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[10]金爽,尹春艳.IGF-Ⅰ、IGF-Ⅱ、IGFBP-1与妊娠期高血压疾病的相关性研究[J].中国计划生育和妇产科,2012,(05):0.
　JIN Shuang,YIN Chun-yan University of South China Teaching Hospital,the Second Peoples Hospital in Guangdong Province,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(6):0.
[11]叶海琼,傅晓冬.microRNA-19a在妊娠期高血压疾病孕妇外周血中的表达[J].中国计划生育和妇产科,2016,(06):0.
　YE Hai-qiong,Fu Xiao-dong,[J].Chinese Journal of Family Planning & Gynecotokology,2016,(6):0.

更新日期/Last Update: 1900-01-01